Company Description
Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance.
These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
We are driven by innovative science to develop novel and transformative drug therapies to treat cancer.
In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviro’s advanced pipeline of drug candidates in Phase 1 and Phase 2 trials.
The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies.
Our drug candidate portfolio currently consists of a pipeline of seven drug candidates, including KROS drugs, which are immunotherapeutics, and ENV antibodies, which are designed to reverse drug resistance that often results as a consequence of the use of cancer therapeutics.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | John S. Yu, M.D. |
Contact Details
Address: 2355 Westwood Blvd., #139 Los Angeles, CA 90064 United States | |
| Phone | (310) 948-2356 |
| Website | kairospharma.com |
Stock Details
| Ticker Symbol | KAPA |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001962011 |
| Employer ID | 46-2993314 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John S. Yu, M.D. | CEO and Chairman of the Board of Directors |
| Neil Bhowmick, Ph.D. | Chief Scientific Officer |
| Ramachandran Murali. Ph.D. | Vice President of Research and Development |
| Doug Samuelson | Chief Financial Officer |
| Hyun W. Bae, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 4, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 24, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 20, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 13, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 1, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 14, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 7, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 29, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 18, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 28, 2023 | DRS/A | [Amend] [Cover] Draft Registration Statement |